Our aim is to make immunotherapy widely accessible to patients who need it. We leverage on our experience in conducting the world’s first and largest T Cell therapy cancer trial, and strive to continually improve on our manufacturing and global supply chain expertise. We believe this will offer patients strong survival benefits and good quality of life.
Our VST treatment shows low toxicity, high efficacy and strong persistence. Together with our research partners, we are rationally designing our treatments to elicit the body’s natural anti-viral immune response against specific cancer targets. We are currently enhancing the reach and efficacy of this core platform by combining it with antibodies, CAR-T receptors and oncolytic virus technologies. Our Virus-Specific T Cell (VST) technology has demonstrated early clinical success in treating solid tumors.
#Thessa ntgh trial#
Today, we are a leader in Virus-Specific T Cell therapy and are conducting the world’s first FDA Phase III T Cell therapy trial in a solid tumor indication. Our goal is to bring hope to cancer patients with no viable treatment options. Tessa Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of cancer immunotherapies.
0 kommentar(er)
